Showing papers in "International Journal of Antimicrobial Agents in 2019"

TL;DR: Following topical application resveratrol has alleviated acne lesions caused by the bacterium Propionibacterium acnes, and recent research suggests that there may be a potential for enhancing the antimicrobial efficacy of certain existing antibiotic classes in combination with resveratography.

TL;DR: Exploration of the repertoire of prokaryotes associated with humans using genome mining or newer culture approaches could be promising strategies for discovering new classes of antibiotics.

TL;DR: The aim of this article is to provide a comprehensive review of all aspects of natural phage therapy.

TL;DR: No correlation was observed between cefiderocol MICs and truncation or loss of porin proteins in meropenem-non-susceptible isolates of E. coli and K. pneumoniae, and there was no clear correlation between carriage of β-lactamases included in the molecular testing algorithm and elevated cefidersol MICs.

TL;DR: This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections in Italy and demonstrates a favourable safety and tolerability profile regardless of the infection type.

TL;DR: It is concluded that cefiderocol demonstrated potent in vitro activity (MIC ≤4 mg/L) against the majority (99.4%, 8903/8954) of clinical isolates of GNB in a recent (2015-2016), multi-continent collection, including carbapenem-non-susceptible isolates.

TL;DR: The contribution of fosfomycin inactivating enzymes in emergence and spread of fOSFomycin resistance currently seems low-to-moderate, but their presence in transferable plasmids may potentially provide the best means for the spread of cAMP regulators and MurA mutations in the future.

TL;DR: This article summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues that show potential in combating multidrug-resistant Gram- negative bacteria.

TL;DR: The widespread presence of carbapenem and polymyxin resistance, including their overlap in 8 nations, represents a continuing risk and increases the threat of infections resistant to both and highlights the urgent need for sufficiently resourced robust antimicrobial resistance surveillance.

TL;DR: The findings suggest that first-line antifungals with good efficacy remain an urgent unmet need and Whilst surgery is fundamental to improving survival, the clinical utility of combination antIFungal therapy or posaconazole monotherapy requires further investigation.

TL;DR: It is suggested that the use of ceftazidime/avibactam in monotherapy or in combination therapy for the treatment of infections due to CRE or CRPsA could show a similar effect on the mortality rate and microbiological cure, however, studies on a larger samples are needed to address this important issue.

TL;DR: Horizontal transfer mediated by IncFII-like plasmids plays an important role in the pandemic expansion of blaKPC-2 among K. pneumoniae ST11 in China.

TL;DR: IVM showed high efficacy in killing vectors of disease-causing parasites such as mosquitoes, sandflies and tsetse flies and to overcome the possibility of drug resistance.

TL;DR: The aim of this paper was to review the epidemiology of C. auris and identify best practices with a panel of experts, in order to provide guidance and recommendations for infection prevention and control measures based on available scientific evidence, existing guidelines and expert opinion.

TL;DR: From experience, ceftazidime-avibactam is an effective drug for treating infections due to OXA-48 CPE, and from these results a better safety profile than the current best available therapy could be expected.

TL;DR: Observations demonstrate that ursolic acid exhibits antiviral activity suggesting that this chemical could be potentially used as a new anti-Rotavirus therapeutic compound.

TL;DR: In conclusion, carbapenem resistance increased among clinically important GNBs, especially among hospital-acquired infections, and the mcr-1 from different species raises the concern of potential dissemination.

TL;DR: Auranofin, an FDA-approved oral antirheumatic drug that has recently been found to possess antibacterial activity, is investigated, showing potent activity against C. difficile isolates and inhibited the growth of vancomycin-resistant enterococci.

TL;DR: First uses of dalbavancin in France were mostly off-label, and most of them were due to BJIs, and often as rescue therapy for severe infections, suggesting that even in off- label situations, dalBavancein seems safe and effective.

TL;DR: For critically ill patients, a versatile meropenem dosing algorithm is proposed, indicating appropriate dosing regimens based on patient- and pathogen-specific information.

TL;DR: This study found that this conjugative plasmid can not only be used as a new tool to remove resistance plasmids and sensitize the recipient bacteria to antibiotics, but can also make the recipient cell acquire immunity against mcr-1.

TL;DR: It is reported that the macrolide antibiotics spiramycin (SPM) and azithromycin (AZM) possess antiviral activities against EV-A71 and CV-A16, and animal experiments showed that AZM possesses stronger anti-infection efficacy than SPM, greatly alleviated the disease symptoms and increased the survival rate in a mouse model severely infected with EV- a71.

TL;DR: The obtained results suggest that the bacteriophages used in this work are a promising approach to control these pathogens involved in orthopedic implant-associated infections.

TL;DR: The findings confirm the efficacy and tolerability of 3TC+DTG in virologically suppressed patients.

TL;DR: Debridement, antibiotics and implant retention (DAIR) was associated with higher failure rates versus non-DAIR (n = 64) and remained unchangeable by time of infection (early/late), antimicrobial resistance (MDR/XDR) and antimicrobials ( colistin/non-colistin) (Breslow-Day).

TL;DR: The literature is evaluated to review optimal dosing and monitoring of intravenous vancomycin in adults, in response to evolving understanding of targets associated with efficacy and toxicity.

TL;DR: Compared with healthy volunteers receiving intravenous ceftazidime, levofloxacin and fosfomycin, dose adjustment is likely to be required in critically ill patients with pneumonia because, in contrast to the systemic administration route, nebulisation of antibiotics achieves high ELF concentrations.

TL;DR: The in vitro activity of C/T observed in this surveillance study suggests that this agent can be considered as a therapeutic option for cUTI and cIAI due to Enterobacterales and P. aeruginosa in ICU patients, particularly when carbapenemase-producing isolates are not involved.

TL;DR: Teicoplanin potentiates peptide LL-37, enhancing the efficacy of the innate defence, and combining the novel peptides with teicoplan in offers potential for enhanced efficacy of treatment of S. aureus infections, including biofilms.